Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorXiaotong Hou
About this trial
The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.
Eligibility criteria
Qualifiers
Age ≥ 18 years old
VA-ECMO or VV-ECMO was accepted after cardiac surgery.
The ECMO treatment team believes that systemic anticoagulation is needed
Sign the informed consent form
Disqualifiers
The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.
Long-term use of anticoagulants before establishment of ECMO
Antiplatelet drugs were used before the establishment of ECMO
Severe liver insufficiency
Trial design
Treatments tested in this trial
- nafamostat mesilate
- unfractionated heparin group
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xiaotong Hou
Lead sponsor
Beijing Anzhen Hospital
Sponsor institution
Source ClinicalTrials.gov